SCHEMBL2194185

SCHEMBL2194185

c1ccc(COc2ccc3ncn(-c4ccc5c(c4)CCC5)c3n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.51
HCAR1 Q9BXC0 1/20 0.46
CSF1R P07333 1/20 0.40
PPARG P37231 1/20 0.39
HRH3 Q9Y5N1 4/20 0.39
ATM Q13315 7/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
HTR1A P08908 1/20 0.38
HTR3A P46098 1/20 0.38
HTR3D Q70Z44 1/20 0.38
HTR3C Q8WXA8 1/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
CYP2D6 P10635 2/20 0.37
RXRA P19793 2/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194786 0.82 PDE10A (0.70) PDE10AHCAR1ATMHTR3EHTR3B
SCHEMBL2195321 0.79 PDE10A (0.60) PDE10AHCAR1ATMHTR3EHTR3B
SCHEMBL2191698 0.79 PDE10A (0.60) PDE10AHCAR1ATMHTR3EHTR3B
SCHEMBL2191972 0.75 HCAR1 (0.55) HCAR1CSF1RATMRXRAGRIN1
SCHEMBL2194911 0.72 PDE10A (0.51) PDE10AHCAR1ATMHTR3EHTR3B
SCHEMBL31068655 0.71 PDE10A (0.48) PDE10AHTR3EHTR3BHTR1AHTR3A
SCHEMBL2195431 0.69 CDK1 (0.47) PDE10AHCAR1HRH3HTR3EHTR3B
SCHEMBL2192506 0.68 EGFR (0.43) HRH3MAOAMAOB
SCHEMBL9300761 0.68 GRM5 (0.46) MAOAMAOB
SCHEMBL2197007 0.67 HCAR1 (0.47) PDE10AHCAR1HTR3EHTR3BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 PDE10A 2688/4885HCAR1 28/4885CSF1R 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.